Bay Colony Advisory Group Inc d b a Bay Colony Advisors Invests $221,000 in Agilent Technologies, Inc. (NYSE:A)

Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in Agilent Technologies, Inc. (NYSE:A) in the fourth quarter, Holdings Channel.com reports. The fund acquired 1,589 shares of the medical research company’s stock, valued at approximately $221,000.

A number of other institutional investors have also recently made changes to their positions in the business. Synovus Financial Corp lifted its position in Agilent Technologies by 2.3% during the 1st quarter. Synovus Financial Corp now owns 6,751 shares of the medical research company’s stock worth $895,000 after acquiring an additional 153 shares during the period. Blair William & Co. IL lifted its position in Agilent Technologies by 7.3% during the 1st quarter. Blair William & Co. IL now owns 28,606 shares of the medical research company’s stock worth $3,785,000 after acquiring an additional 1,957 shares during the period. Sequoia Financial Advisors LLC lifted its position in Agilent Technologies by 52.1% during the 1st quarter. Sequoia Financial Advisors LLC now owns 2,334 shares of the medical research company’s stock worth $309,000 after acquiring an additional 799 shares during the period. Vanguard Group Inc. lifted its position in Agilent Technologies by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 24,531,170 shares of the medical research company’s stock worth $3,246,209,000 after acquiring an additional 261,435 shares during the period. Finally, Zions Bancorporation N.A. lifted its position in Agilent Technologies by 10.8% during the 1st quarter. Zions Bancorporation N.A. now owns 2,880 shares of the medical research company’s stock worth $381,000 after acquiring an additional 281 shares during the period.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Michael R. Mcmullen sold 52,297 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $150.00, for a total transaction of $7,844,550.00. Following the completion of the sale, the chief executive officer now directly owns 253,909 shares in the company, valued at approximately $38,086,350. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, Director Heidi Fields sold 1,658 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total transaction of $239,315.72. Following the transaction, the director now directly owns 54,976 shares in the company, valued at approximately $7,935,235.84. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Michael R. Mcmullen sold 52,297 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $150.00, for a total value of $7,844,550.00. Following the transaction, the chief executive officer now owns 253,909 shares in the company, valued at $38,086,350. The disclosure for this sale can be found here. In the last three months, insiders sold 61,610 shares of company stock worth $9,220,333.

Analyst Upgrades and Downgrades

A number of analysts have commented on A shares. JPMorgan Chase & Co. lifted their price target on Agilent Technologies from $140.00 to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 20th. Citigroup boosted their price objective on Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. StockNews.com raised Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 19th. Oppenheimer boosted their price objective on Agilent Technologies from $67.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday, March 26th. Finally, Barclays boosted their price objective on Agilent Technologies from $125.00 to $135.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. One analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $141.29.

Agilent Technologies Price Performance

Shares of Agilent Technologies stock opened at $136.71 on Wednesday. The company has a quick ratio of 2.04, a current ratio of 2.68 and a debt-to-equity ratio of 0.41. Agilent Technologies, Inc. has a twelve month low of $96.80 and a twelve month high of $151.58. The business has a 50-day moving average price of $141.19 and a 200 day moving average price of $129.45. The firm has a market cap of $40.06 billion, a PE ratio of 32.55, a P/E/G ratio of 4.26 and a beta of 1.11.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Tuesday, February 27th. The medical research company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.22 by $0.07. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The company had revenue of $1.66 billion during the quarter, compared to analyst estimates of $1.59 billion. During the same period in the previous year, the business earned $1.37 EPS. Agilent Technologies’s quarterly revenue was down 5.5% on a year-over-year basis. Sell-side analysts predict that Agilent Technologies, Inc. will post 5.51 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 24th. Shareholders of record on Tuesday, April 2nd will be paid a dividend of $0.236 per share. The ex-dividend date is Monday, April 1st. This represents a $0.94 annualized dividend and a yield of 0.69%. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.38%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.